MAIA Biotechnology

MAIA Biotechnology

  • Founded: 2018
  • Location: Chicago, IL
  • Employee range: 1 - 10
  • Clinical stage: Clin2
  • Therapy area: NSCLC
  • Drug types: ONC
  • Lead product: THIO-101 (partner: Regeneron)
  • Product link:
  • Funding: $5.75M stock Apr 2023; $10M IPO Jul 2022; $2.4M Mar 2022; $6M Oct 2021; $8M May 2021

job board

Short description:

Peptide Cancer Therapies

Drug notes:

THIO-102 Clin1 multiple cancers; THIO-103 Clin1 multiple cancers; 3 programs RD oncology

Long description:

MAIA Biotechnology is developing novel immune-oncology therapies to treat cancer. MAIA’s lead drug candidate, THIO, is an investigational dual mechanism of action drug that is recognised by the protein telomerase that adds telomeres to the ends of DNA. On recognition of THIO, the compound gets incorporated into the telomere structure resulting in rapid cell death. As telomerase is present in more than 85% of human cancers contributing greatly to the proliferation and reproductive immortality of cancer cells, MAIA is testing THIO in many cancer types. Currently, THIO is being tested in clinical trials for non-small cell lung cancer.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy